Comparison of two antibiotic regimens in patients with positive VAP caused by Acinetobacter

Comparison of two antibiotic regimens in patients with positive Ventilator-associated pneumonia caused by Acinetobacter: an open-label clinical trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221102056386N2

Enrollment

102

Registered

2023-04-17

Start date

2023-04-20

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acinetobacter infection. Pneumonia due to other specified bacteria

Interventions

Intervention 1: Intervention group 1: Patients in this group receive 9 million units of colistin as a loading dose and then 4.5 million units of colistin every 12 hours as an intravenous infusion with

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Ventilator-Associated Pneumonia (VAP) confirmed by a doctor age 18 or older Hospitalization in the intensive care unit (ICU) obtaining informed consent from the patient or the patient's companion history of sensitivity to antibiotics in the laboratory

Exclusion criteria

Exclusion criteria: Organ transplant or bone marrow transplant Being treated for human immunodeficiency virus (HIV) Receiving another antibiotic from another hospital within less than 72 hours Pregnancy Having an incurable disease Blood malignancy without a treatment plan Resistance to therapeutic antibiotics Having another infection along with Ventilator-associated pneumonia (VAP)

Design outcomes

Primary

Measure	Time frame
Determining the effectiveness of the intervention. Timepoint: During the study period. Method of measurement: Examination of clinical symptoms during the intervention period.	—

Secondary

Measure	Time frame
Comparison of hospitalization in ICU and hospital. Timepoint: Duration of the study. Method of measurement: check list.;The effect of treatment on the duration of the patient's recovery during the intervention period. Timepoint: Duration of the study. Method of measurement: Clinical symptoms and laboratory tests.;Mortality. Timepoint: end of the study. Method of measurement: check list.;Kidney function. Timepoint: duration of the study. Method of measurement: Measurement of creatinine and blood urea nitrogen levels.	—

Measure

Time frame

Comparison of hospitalization in ICU and hospital. Timepoint: Duration of the study. Method of measurement: check list.;The effect of treatment on the duration of the patient's recovery during the intervention period. Timepoint: Duration of the study. Method of measurement: Clinical symptoms and laboratory tests.;Mortality. Timepoint: end of the study. Method of measurement: check list.;Kidney function. Timepoint: duration of the study. Method of measurement: Measurement of creatinine and blood urea nitrogen levels.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactsaeed shoja

Bandare-abbas University of Medical Sciences

shojasaeed@gmail.com+98 76 3333 7192

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026